Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) Assets Average (2022 - 2025)

Stoke Therapeutics has reported Assets Average over the past 4 years, most recently at $389.3 million for Q4 2025.

  • Quarterly results put Assets Average at $389.3 million for Q4 2025, up 37.85% from a year ago — trailing twelve months through Dec 2025 was $389.3 million (up 37.85% YoY), and the annual figure for FY2025 was $345.0 million, up 38.03%.
  • Assets Average for Q4 2025 was $389.3 million at Stoke Therapeutics, up from $372.4 million in the prior quarter.
  • Over the last five years, Assets Average for STOK hit a ceiling of $395.7 million in Q2 2025 and a floor of $216.8 million in Q1 2024.
  • Median Assets Average over the past 4 years was $282.4 million (2024), compared with a mean of $295.9 million.
  • Biggest five-year swings in Assets Average: dropped 19.4% in 2024 and later soared 56.49% in 2025.
  • Stoke Therapeutics' Assets Average stood at $266.8 million in 2022, then dropped by 12.27% to $234.1 million in 2023, then increased by 20.64% to $282.4 million in 2024, then surged by 37.85% to $389.3 million in 2025.
  • The last three reported values for Assets Average were $389.3 million (Q4 2025), $372.4 million (Q3 2025), and $395.7 million (Q2 2025) per Business Quant data.